secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2022-07-06T23:59:59+00:00
Accession:  0001564590-22-025392
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera loses Chief Business Officer Neil Berkley effective June 29, 2022
---------------------------------------------------------------------------

- Neil Berkley departed as Chief Business Officer effective June 29, 2022; not due to any disagreement with the Company.
- Berkley qualifies for severance benefits under the Company's Executive Severance Plan (terms previously disclosed in proxy statement).
- No successor named in the filing; departure is effective immediately.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000156459022025392/0001564590-22-025392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000156459022025392/abcl-8k_20220629.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-025392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer